Insider Selling: ASP Isotopes (NASDAQ:ASPI) COO Sells 8,438 Shares

Posted by Brian Himes on Sep 11th, 2026

ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) COO Robert Ainscow sold 8,438 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $4.29, for a total value of $36,199.02. Following the transaction, the chief operating officer owned 2,248,441 shares in the company, valued at approximately $9,645,811.89. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The shares were sold at an average price of $3.90, for a total value of $97,500.00.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $3.59 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. The stock’s fifty day moving average price is $4.21 and its two-hundred day moving average price is $5.16. ASP Isotopes Inc. has a one year low of $3.51 and a one year high of $14.49. The firm has a market cap of $550.38 million, a price-to-earnings ratio of -2.72 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The firm had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analyst Ratings Changes

A number of brokerages have issued reports on ASPI. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.00.

View Our Latest Report on ASP Isotopes

Institutional Trading of ASP Isotopes

Several large investors have recently made changes to their positions in ASPI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in ASP Isotopes by 9.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock valued at $148,000 after buying an additional 2,709 shares during the period. Rhumbline Advisers lifted its position in ASP Isotopes by 20.9% in the 2nd quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock valued at $581,000 after acquiring an additional 13,668 shares in the last quarter. XTX Topco Ltd acquired a new position in ASP Isotopes during the 2nd quarter valued at about $178,000. New York State Common Retirement Fund boosted its stake in ASP Isotopes by 418.2% during the 2nd quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after purchasing an additional 13,800 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in ASP Isotopes by 2,205.0% during the 2nd quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock worth $3,468,000 after purchasing an additional 450,776 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

(Get Free Report)

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.